Pearl vs Retrace
Side-by-side comparison of Pearl and Retrace. See how they stack up in pricing, features, and real-world use cases.
Pearl
by Pearl · Los Angeles, CA
Clinical AI: Diagnostic Imaging
Contact Sales
- Detects more pathology types than most competitors in a single analysis
- Widest PMS integration coverage, working with 5+ major systems
- Practice Intelligence adds business analytics on top of clinical detection
- Enterprise pricing model; cost unclear until sales conversation
- Detection accuracy is condition-dependent, strongest on caries, weaker on marginal bone loss
- 01 Multi-condition screening on bitewings and periapicals
- 02 Case acceptance conversations with AI-annotated x-rays
- 03 Practice-wide quality metrics via the analytics dashboard
Pearl covers the widest range of dental pathologies in a single FDA-cleared product. If your practice wants one AI tool that screens for caries, lesions, calculus, and bone loss simultaneously, Pearl is the leading option. The Practice Intelligence dashboard adds value for multi-location practices tracking clinical consistency. Confirm pricing against your patient volume before committing.
Retrace
by Retrace · Unknown
Clinical AI: Treatment Planning
Contact Sales
- Addresses the treatment planning and case presentation workflow rather than diagnostic imaging
- May complement diagnostic AI tools like Overjet, Pearl, or VideaHealth
- No confirmed FDA 510(k) clearance. Practices should verify regulatory status before clinical use
- Less publicly documented than established dental AI competitors
- 01 Generating treatment plans with AI assistance
- 02 Presenting treatment options visually to patients
Retrace targets the treatment planning and case presentation side of dental AI, which is a different niche from the diagnostic imaging tools (Overjet, Pearl, VideaHealth) that dominate the dental AI conversation. However, we were unable to confirm FDA 510(k) clearance for Retrace as of February 2026. The product appears in dental AI market listings and directories, but practices should independently verify its regulatory status and clinical validation before incorporating it into clinical workflows. If you are evaluating dental AI tools, start with the FDA-cleared diagnostic platforms and assess Retrace as a potential complement for the treatment planning workflow, after confirming its current regulatory standing.